Literature DB >> 11739678

Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response.

Valérie Molinier-Frenkel1, Renée Lengagne, Florence Gaden, Saw-See Hong, Jeannine Choppin, Hanne Gahery-Ségard, Pierre Boulanger, Jean-Gérard Guillet.   

Abstract

The capacity of recombinant adenoviruses (rAd) to induce immunization against their transgene products has been well documented. In the present study, we evaluated the vaccinal adjuvant role of rAd independently of its vector function. BALB/c mice received one subcutaneous injection of a mixture of six lipopeptides (LP6) used as a model immunogen, along with AdE1 degrees (10(9) particles), a first-generation rAd empty vector. Although coinjected with a suboptimal dose of lipopeptides, AdE1 degrees significantly improved the effectiveness of the vaccination, even in the absence of booster immunization. In contrast to mice that received LP6 alone or LP6 plus a mock adjuvant, mice injected with AdE1 degrees plus LP6 developed both a polyspecific T-helper type 1 response and an effector CD8 T-cell response specific to at least two class I-restricted epitopes. The helper response was still observed when immunization was performed using LP6 plus a mixture of soluble capsid components released from detergent-disrupted virions. When mice were immunized with LP6 and each individual capsid component, i.e., hexon, penton base, or fiber, the results obtained suggested that hexon protein was responsible for the adjuvant effect exerted by disrupted Ad particles on the helper response to the immunogen. Our results thus have some important implications not only in vaccinology but also for gene therapy using rAd vectors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11739678      PMCID: PMC135719          DOI: 10.1128/jvi.76.1.127-135.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Characterization of a multi-lipopeptides mixture used as an HIV-1 vaccine candidate.

Authors:  C Klinguer; D David; M Kouach; J M Wieruszeski; A Tartar; D Marzin; J P Levy; H Gras-Masse
Journal:  Vaccine       Date:  1999-09       Impact factor: 3.641

2.  Adenovirus fiber protein (FP) functions as a mitogen and an adjuvant.

Authors:  M Gibson; P Tiensiwakul; N Khoobyarian
Journal:  Cell Immunol       Date:  1982-11-01       Impact factor: 4.868

3.  Comparative optical properties of free and assembled hexon capsomeres of human adenovirus type 2.

Authors:  P A Boulanger; C Devaux; M H Loucheux-Lefebvre
Journal:  FEBS Lett       Date:  1977-12-20       Impact factor: 4.124

4.  Characterization of adenovirus protein IX.

Authors:  P Boulanger; P Lemay; G E Blair; W C Russell
Journal:  J Gen Virol       Date:  1979-09       Impact factor: 3.891

5.  Recombinant adenovirus induces maturation of dendritic cells via an NF-kappaB-dependent pathway.

Authors:  A E Morelli; A T Larregina; R W Ganster; A F Zahorchak; J M Plowey; T Takayama; A J Logar; P D Robbins; L D Falo; A W Thomson
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms.

Authors:  C Wohlfart
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

7.  Hexon trimerization occurring in an assembly-defective, 100K temperature-sensitive mutant of adenovirus 2.

Authors:  N Morin; P Boulanger
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

8.  Adenovirus fiber protein produces synthesis of interferon in mouse spleen and macrophage cultures.

Authors:  P Tiensiwakul; N Khoobyarian
Journal:  Intervirology       Date:  1983       Impact factor: 1.763

9.  Determination of the nucleotide sequence for the penton-base gene of human adenovirus type 5.

Authors:  R Neumann; J Chroboczek; B Jacrot
Journal:  Gene       Date:  1988-09-15       Impact factor: 3.688

10.  Adenovirus polypeptide IX revealed as capsid cement by difference images from electron microscopy and crystallography.

Authors:  P S Furcinitti; J van Oostrum; R M Burnett
Journal:  EMBO J       Date:  1989-12-01       Impact factor: 11.598

View more
  60 in total

1.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 4.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

5.  [F-18]-Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model.

Authors:  Coralie Chaise; Emmanuel Itti; Yolande Petegnief; Evelyne Wirquin; Christiane Copie-Bergman; Jean-Pierre Farcet; Marie-Hélène Delfau-Larue; Michel Meignan; Jean-Noël Talbot; Valérie Molinier-Frenkel
Journal:  Cancer Immunol Immunother       Date:  2006-12-14       Impact factor: 6.968

6.  Implications of the innate immune response to adenovirus and adenoviral vectors.

Authors:  Seth M Gregory; Shoab A Nazir; Jordan P Metcalf
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

7.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas.

Authors:  Mirjana Urosevic; Kazuyasu Fujii; Bastien Calmels; Elisabeth Laine; Nikita Kobert; Bruce Acres; Reinhard Dummer
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

9.  Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.

Authors:  Jonathan B Rosenberg; Bishnu P De; Martin J Hicks; Kim D Janda; Stephen M Kaminsky; Stefan Worgall; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2013-06       Impact factor: 5.695

10.  Evaluation of cross-reactive cell-mediated immune responses among human, bovine and porcine adenoviruses.

Authors:  A Sharma; M Tandon; Y S Ahi; D S Bangari; R Vemulapalli; S K Mittal
Journal:  Gene Ther       Date:  2010-02-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.